Background: Patient long-term adherence to b-blockers, HMG-CoA reductase inhibitors (statins), and angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin receptor blockers (ARBs) after acute myocardial infarction (AMI) is alarmingly low. It is unclear how prevalent patient adherence may be across small geographic areas and whether this geographic prevalence may vary.
C linical guidelines recommend long-term use of b-blockers, HMG-CoA reductase inhibitors (statins), angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin receptor blockers (ARBs) as secondary preventive therapies after acute myocardial infarction (AMI). 1, 2 Recent studies have shown considerable improvements in the prescribing of the preventive therapies at discharge after years of implementation of the Get With The Guidelines program. [3] [4] [5] However, evidence-based therapies may not be able to optimally reduce mortality and morbidity after AMI if patients do not take them as directed. The benefit of these preventive therapies depends on long-term adherence. [6] [7] [8] Adherence to the evidence-based therapies are typically defined as >80% of time a patient is covered with prescription supply. 7 In a recent population-based longitudinal study of 31,455 elderly AMI survivors, patients who had low adherence to the evidenced-based therapies had a 25% higher mortality risk (95% CI, 9%-42%) as compared with patients who had high adherence. 7 It was also shown that nonadherent patients had a 44% higher likelihood (95% CI, 15%-79%) of 1-year mortality than adherent patients after AMI hospital discharge. 8 Another study also showed that AMI patients who were adherent had a 53% lower risk for mortality (95% CI, 1%-79%) and 81% lower risk for recurrent AMI (95% CI, 53%-92%). 6 However, patient medication adherence after AMI has been shown to be worryingly low in general. One year after hospital discharge, approximately half of Medicare patients have been shown to be nonadherent to statins, b-blockers, and ACEI/ARB treatments. [9] [10] [11] It has also been argued that medication adherence should be a priority for health care reform. 12 From a public health perspective, an efficient national intervention program may be enhanced by targeting high-risk populations, and also areas with a high prevalence of nonadherence. Previous studies have shown that there were considerable regional variations in prescribing b-blockers, statins, and ACEIs/ARBs at discharge after AMI, which indicated difference in the quality of care across regions. [13] [14] [15] [16] [17] [18] However, it is unclear whether small-area variation exists in patient long-term adherence to the prescribed preventive therapies after AMI discharge, and the extent of this variation. If such variation in patient adherence to the evidencebased preventive therapies exists, identifying these regions with high prevalence of patient nonadherence may facilitate future research to design more efficient and targeted public health programs and policies to address patient nonadherence to evidence-based preventive therapies.
Therefore, this study aimed to: (1) assess patient adherence to the 3 evidence-based therapies post-AMI among a national cohort of older adults who survived AMI in the 12 months after their discharge across Dartmouth Atlas Hospital Referral Regions (HRRs) after adjustment of nonmodifiable patient characteristics; (2) to compare and identify the HRRs with high prevalence of nonadherence; and (3) to assess the extent of the variation in patient adherence across HRRs and whether the variation added explanation or prediction power of individual patient adherence status in addition to individual patient risk factors.
METHODS

Setting and Population
The cohort for this study included all Medicare beneficiaries who were: (1) 65 years old and above; (2) continuously enrolled in the Medicare fee-for-service and prescription Part D programs at least 12 months before and until the end of the study period (or death) after an index AMI hospitalization; (3) hospitalized for the index AMI between January 1, 2008 and December 31, 2008 and survived at least 30 days after discharge; (4) were discharged to home or to skilled nursing and long-term care facilities and had any prescription claims within 30 days after discharge. Hospitalization with AMI was defined as having an international classification of diseases 9 code of 410.x1 as the primary or secondary discharge diagnosis in Medicare inpatient claims. [19] [20] [21] The first AMI hospitalization in the study period was defined as the index AMI hospitalization for each subject.
Primary data used for this study were Medicare service claims and files from the Center for the Medicare and Medicaid Services Medicare Chronic Condition Data Warehouse (CCW) from 2007 to 2009. 22 The CCW files includes inpatient, outpatient, skilled nursing facility, carrier (physician office visits), and prescription Part D event service claims files. All CCW files are linked by an encrypted and unique CCW identifier number for each beneficiary. Other data included the HRRs boundary files, which were linked to CCW files by ZIP codes of patient residence.
Treatment Measurement
The use of b-blockers, ACEIs/ARBs, or statins after AMI was defined as: (1) filled a prescription within the drug class within 30 days after hospital discharge or (2) had a prescription supply >30 days from the last prescription filled before the AMI admission and filled a prescription for the same class of the drug within 60 days after discharge. The specific drug was identified through national drug codes in the Medicare Part D prescription event files in the Medicare CCW.
Adherence Measurement
Adherence was measured as the proportion of days covered (PDC) by the prescription supply calculated from the prescription refill records in the prescription Part D event files in the 12 months (or until death if death occurred within 12 mo) post-AMI discharge among patients who had the preventive therapies within 30 days after AMI discharge. 23 The adherence measure was also adjusted for overstock of prescription supply from refills and hospital stays during the study period after AMI discharge. Conforming to current literature, a patient is defined as adherent if he/she had Z80% of days covered with prescription supply in the study period. 7
Measurement of Baseline Characteristics/ Covariates
Age, sex, and race were determined by using CCW enrollment summary files from the index year. Median income for 65 years and older was measured at Census Block Groups residence level using 2010 US Census data. Comorbidities were measured by the Charlson comorbidity index in the 12 months before the index AMI admission using CCW claims files. 24 Other variables included whether a subject was in the Medicare Part D benefit gap (doughnut hole) before the index AMI admission, diagnosis of cardiovascular disease, and other related risk factors in the 12-month baseline (including AMI, coronary artery bypass surgery, stent/percutaneous transluminal coronary angioplasty, stroke/transient ischemic attack, unstable angina, ischemic heart disease, heart failure, atrial fibrillation, peripheral vascular disease, hypertension, diabetes, and hyperlipidemia), baseline potential contraindication or intolerant conditions (chronic kidney disease, chronic obstructive pulmonary disease, asthma, liver disease, angioedema, hyperkalemia, hypotension, sinus bradycardia, heart block, and rhabdomyolysis/other myopathy), prescriptions of b-blockers, ACEIs/ARBs, or statins in the 6 months before the index AMI, AMI type (subendocardial or transmural infarction), procedures (coronary artery bypass surgery, stent/percutaneous transluminal coronary angioplasty, cardiac catheterization, infusion of thrombolytic, infusion of platelet inhibitors) or complications (congestive heart failure, cardiogenic shock, acute renal failure, hypotension, cardiac dysrhythmias) during the index AMI hospitalization, and total intensive care unit and inpatient length of stay for the index AMI. Other factors measured include discharge destination (home or skilled nursing facilities) and risk factors that may be associated with nonadherence such as the total number of different prescription medications used (polypharmacy) and diagnosis of dementia in the 12-month baseline. Those characteristics were measured using files based on the standardized algorithms in the CCW and other algorithms applied in the literature. 22, 24, 25 
Measurement of Small-Area Variation in Adherence
To assess small-area variation in patient adherence to the 3 evidence-based therapies post-AMI, we measured the adjusted proportion of patients who were adherent to each of the therapies across Dartmouth HRRs. The Dartmouth HRRs represent regional health care markets for tertiary medical care that generally require the services of a major referral center. 15 The regions were defined by determining where patients were referred for major cardiovascular surgical procedures and for neurosurgery. Each HRR has at least 1 city where both major cardiovascular surgical procedures and neurosurgery are performed. We assigned each patient to one of the HRRs on the basis of his/her ZIP code of residence. The adjusted proportion of patients adherent to a therapy across HRRs was calculated as the predicted number of patients adherent to a therapy divided by the total number of the patients in a HRR. The predicted number of patients adherent to a therapy was computed by summing all patients' probabilities of being adherent in each HRR. The probability of being adherent for each individual patient was estimated using a mixed-effect hierarchical logistic regression model with HRRs as random effects and random intercepts (SAS GLIMMIX procedure). [26] [27] [28] The model was adjusted for all measured baseline patient characteristics and also the clustering of patients and small and unequal sample sizes across HRRs. [26] [27] [28] Sensitivity analysis was also performed for testing and adjusting for spatial autocorrelation.
Analysis
The characteristics of patients who initiated each therapy and the proportion of patients who were adherent to each therapy were described. The distribution of mean PDC by a therapy post-AMI discharge to a therapy across HRRs was assessed using a box plot. The HRRs were ranked by the adjusted proportion of patients adherent to each of the 3 therapies. To compare adherence rate across HRRs and identify HRRs with higher prevalence of nonadherence, we used control chart to plot the adjusted proportion of patients adherent to a therapy across HRRs to identify the HRRs with the proportion below the 5th percentile. 29 To assess the extent of the variation in patient adherence across HRR, we calculated the intraclass (intracluster) correlation coefficient (ICC). 30 The ICC is a ratio between the between-cluster variance and the total variance of be-tween-cluster and within-cluster variance. The mean and the 95% confidence intervals of the ICC were generated by the bootstrap (resampling) of 1000 iterations with replacement from all patients in the cohort. 31 To assess whether small-area variation in adherence adds prediction of individual patient adherence beyond individual patient risk factors, we compared the c-statistics [Area Under the Curve (AUC)] from logistic regression models with measured patient characteristics and with both patient characteristics and the adjusted proportion of adherent patients across HRRs.
All analyses were conducted using SAS version 9.3 (SAS Institute Inc., Cary, NC), and the maps were created using ArcGIS version 10 (ESRI Inc., Redlands, CA).
RESULTS
A total of 85,017 patients were included in the final analysis with 64,939 (76%) using b-blockers, 52,185 (61%) using statins, and 47,127 (55%) using ACEIs/ARBs within 30 days after discharge. About 66% users of b-blockers, 66% users of statins, and 63% users of ACEIs/ARBs were adherent during the 12 months after discharge. Table 1 presents the characteristics of patients who initiated the various preventive therapies and the proportion of patients adherent for those respective characteristics. For example, approximately 58%, 59%, and 56% of patients who initiated b-blockers, ACEIs/ARBs, and statins were female, respectively. The proportion of patients adherent to b-blockers increased from 65% in those 65-74 years old to 68% in those 85 years and older, from 62% to 64% for ACEIs/ARBs, and from 65% to 68% for statins. The proportion of patients adherent to bblockers decreased from 67% among patients with a Charlson comorbidity index of 0 to 65% among patients with a Charlson comorbidity index of Z9. Patients who had potential contraindicative or intolerant conditions to the preventive therapies had lower adherence rates.
The distribution of mean adherence (PDC) across HRR is presented in Appendix 1 (Supplemental Digital Content 1, http://links.lww.com/MLR/A644). The mean (SD) is 0.77 (0.031), 0.80 (0.034), 0.079 (0.033) for ACEIs/ARBs, bblockers, and statins, respectively. Figure 1 shows the mapping of the proportion of patients adherent to the 3 preventive therapies in the 12 months after discharge across HRRs after adjustment for nonmodifiable factors (patient baseline sociodemographic and clinical characteristics). The proportion of patients adherent to b-blockers ranged from 58% to 74% across HRRs, from 58% to 67% for ACEIs and ARBs, and from 58% to 73% for statins. The patterns of the regional variation in adherence were similar for the 3 therapies. In general, HRRs in the south tend to have lower proportion of patients adherent to the 3 therapies than the HRRs in the north.
Figures 2A-C present the control chart plot of each HRR's adjusted proportion of patients adherent to the 3 preventive therapies, respectively. Each circle in the plots represents a HRR. The 3 dashed reference lines represent the 95th percentile, median, and 5th percentile of the adjusted proportion of patients adherent to a preventive therapy. The median of the adjusted proportion of patients adherent to bblockers across HRRs was 66%, which means that half of the HRRs had < 66% of patients adherent to b-blockers. The median of the adjusted proportion of patients adherent to statins and ACEIs/ARBs were 66% and 63%, respectively. Consistent results were found in sensitivity analysis of adjusting for spatial autocorrelation in the mixed-effect hierarchical logistic regression model. The 5th percentile of adjusted proportion of patients adherent across HRRs was 61%, 60%, and 62% for b-blockers, ACEI/ARBs, and statins, respectively. Appendix 2 (Supplemental Digital Content 2, http://links.lww.com/ MLR/A645) listed the HRRs below the 5th percentile of the adjusted proportion of patients adherent for each evidencebased preventive therapy. HRR with lowest patient adherence to b-blockers was Orlando and Jacksonville, Florida for ACEIs/ARBs, and El Paso, Texas for statins. Table 2 presents the ICC to assess the extent of the variation in patient adherence to the 3 preventive therapies across HRRs. The ICC ranged from 0.041 for statins, to 0.050 for ACEIs/ARBs and to 0.053 for b-blockers. Table 3 presents the difference in the AUC between the logistic model with patient characteristics and the logistic model with both patient characteristics and the adjusted proportion of patients adherent across HRRs. Adding the variation in the proportion of patients adherent across HRRs increased the AUC by 0.014 for b-blockers, 0.009 for ACEIs/ARBs, and 0.012 for statins (P < 0.0001).
DISCUSSION
In our study of 85,017 elderly AMI survivors in 2008, we found that nonadherence was highly prevalent across the HRRs in the United States. Half of the 306 HRRs had approximately < 65% of patients adherent to the 3 evidencebased preventive therapies in the 12 months post-AMI. The range in the adjusted proportion of patients adherent to the 3 evidence-based AMI therapies across HRRs were about 8 to 16 percentage points. The ICC, which measures the extent of the adherence variation across HRRs as compared variation across individuals, was 0.041-0.053. In a review of 31 cluster-based studies on health outcomes and clinical practice, it was shown that the median ICC was 0.005 with the interquartile ranging from 0 to 0.021 after adjusting for individual and cluster-level characteristics. 32 Another study of 188 ICCs for primary care health services and binary health outcomes found that the median ICC was 0.051 with interquartile from 0.011 to 0.094. 33 Therefore, the ICC value of 0.041-0.053 in our study suggests a moderate variation across HRRs in patient adherence relatively to typical regional variations in health care settings.
We ranked the HRRs based on the adjusted proportion of patients adherent and listed the HRRs below the 5th percentile. There are limitations of using quantitative comparison as performance indicators as it remains difficult to determine the meaningful extent of differences in the comparison to differentiate individual clusters in their performance. 29, 34, 35 However, HRRs with the adjusted proportion of patients adherent below the 5th percentile may be reasonably considered as outliers.
The considerable increased hospital readmission and mortality risk associated with nonadherence to the evidencebased preventive therapies has received increasing attention from clinicians, researchers, and policy makers. 10, 12, [36] [37] [38] [39] [40] Given the prevalent nonadherence to evidence-based preventive therapies among patients, a public health approach to address nonadherence may be an important factor. In this study, the observed moderate variation in patient adherence across relatively small health service regions was unexplained by nonmodifiable factors such as patient sociodemographic and clinical characteristics. This unexplained small-area variation in patient adherence may suggest that modifiable factors such as provision and quality of care may play an important role. Studies have suggested that the geographic variation in prescribing of evidence-based therapies may stem from the disparities in the provision of quality of care and processes across regions. [13] [14] [15] [16] [17] [18] A complexity in the processes of care potentially impacting patient long-term adherence is the involvement of patients, multiple care providers including cardiologists, family care providers, and pharmacists across institution and community settings. It has also been shown that care processes and provisions such as continuity of care (eg, follow-up care and medication reconciliation), coordination of care (eg, "therapeutic complexity"-having multiple prescribers, pharmacies, and care providers), and provider-patient communication affected patient adherence to prescribed preventive therapies. [41] [42] [43] It is possible that differences in the quality of care process and provision and health literacy level across HRRs may be important contributors to the variation in patient adherence to evidence-based therapies unexplained by patient sociodemographic and clinical characteristics. Future studies are necessary to identify the differences in care process and provision that may lead to the small-area variation in patient adherence. National policies and programs, for example, the Health Plan Employer Data and Information Set Measures and the Get With The Guidelines program, are in place to enhance the prescribing of evidence-based therapies for AMI care, and improvements have been achieved in prescribing b-blockers, statins, and ACEIs/ARBs at discharge. [3] [4] [5] However, there is a need for more national programs and policies that specifically aim to improve the care process associated with patient adherence to the evidence-based preventive therapies. Our study suggests that it may be useful for programs to add emphasis on small health service areas with high prevalence of nonadherence. Reasons for patient nonadherence are usually multifactorial. 12, 38, 40, 44 The proportion of patients adherent across HRRs added a statistically significant but mild prediction of individual patient adherence beyond nonmodifiable individual patient characteristics. The mildly added prediction for individual patients suggests that program with emphasis on small health services areas with high prevalence of nonadherence needs to be coupled with interventions on various individual risk factors to improve adherence.
Limitations of this study are common to all studies using health care administrative claims. To address those limitations, we applied previously validated algorithms in the literature to measure index AMI with a positive predictive value of 89%-97%. [19] [20] [21] Our data cannot elucidate whether nonadherence was due to adverse side effects. However, the 3 evidence-based therapies are generally well tolerated, and the incidence of adverse side effects is low; it is also unlikely that adverse effects would be differential across geographic regions. 7 We have also adjusted for potential intolerant and contraindicative conditions to the use of the therapies at baseline. We used prescription refill records to measure adherence without information on actual medication taking. However, prescription refill records have been shown to have good validity and correlation with pill counts. 7, 23 The nature of retrospective cohort analysis using claims files does not allow us to measure all potential confounding factors. It remains possible that unmeasured confounders may contribute to the observed variation in the prevalence of nonadherence across HRRs. However, it is suggested that important bias in regional variation in medical practice will be rare, and regional variation in medical practice as proxy for confounder misclassification will typically be negligible. 45 Patients discharged to home may have different adherence from that of patients discharged to skilled nursing facilities. Future study may be needed to assess whether small-area variation in patient adherence may differ by discharge location. Our study has several strengths. To the best of our knowledge, the small-area variation in patient adherence to preventive therapies has not been assessed in other studies. We utilized a nationally representative cohort of 100% Medicare patient samples who were enrolled in the fee-for-service and Part D program and recent 2007-2009 data representing contemporary settings.
In summary, moderate variation across small geographic area in patient adherence to evidence-based preventive therapies exists among older adults post-AMI. This moderate small-area variation in patient adherence was unexplained by nonmodifiable patient sociodemographic and clinical characteristics.
